Cargando…

Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer

BACKGROUND: The DYNAMIC trial investigated the use of circulating tumor DNA (ctDNA) to guide adjuvant treatment decisions in stage II colon cancer. Despite the DYNAMIC trial’s assertion that a ctDNA-guided approach could minimize the use of adjuvant treatment without compromising recurrence-free sur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olivier, Timothée, Haslam, Alyson, Prasad, Vinay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485976/ https://www.ncbi.nlm.nih.gov/pubmed/37679732 http://dx.doi.org/10.1186/s12916-023-03037-9

Ejemplares similares

ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC)
por: Masfarré, Laura, et al.
Publicado: (2021)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology Randomized Clinical Trials
por: Olivier, Timothée, et al.
Publicado: (2022)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
por: Olivier, Timothée, et al.
Publicado: (2023)

ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm
por: Naidoo, Mahendra, et al.
Publicado: (2021)

Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers
por: Haslam, Alyson, et al.
Publicado: (2023)

Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity
por: Olivier, Timothée, et al.
Publicado: (2023)

The clinical application of ctDNA to predict response to neoadjuvant chemoradiotherapy in patients with locally-advanced rectal cancer
por: Pezeshki, Parmida Sadat, et al.
Publicado: (2023)

Additional considerations for "checklists to guide the supportive and critical care of tuberculous meningitis"
por: Behl, Anuradha, et al.
Publicado: (2020)

Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials
por: Ahmed, Nibras, et al.
Publicado: (2022)

What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020)
por: Jenei, Kristina, et al.
Publicado: (2022)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Early detection and stratification of lung cancer aided by a cost-effective assay targeting circulating tumor DNA (ctDNA) methylation
por: Wang, Zhoufeng, et al.
Publicado: (2023)

ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)
por: Slater, Susanna, et al.
Publicado: (2023)

Complete response to immunotherapy in a patient with high-risk stage III colorectal cancer after ctDNA-guided detection of early adjuvant treatment failure
por: Lucchesi, Nicholas, et al.
Publicado: (2023)

Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC
por: Wang, Bolin, et al.
Publicado: (2023)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

The Pathological Features of Colorectal Cancer Determine the Detection Performance on Blood ctDNA
por: He, Na, et al.
Publicado: (2018)

The association of blood ctDNA levels to mutations of marker genes in colorectal cancer
por: Bai, Fei, et al.
Publicado: (2023)

Additional considerations for assessing COVID-19 impact on dengue transmission
por: Yek, Christina, et al.
Publicado: (2022)

Estimation of US patients with cancer who may respond to cytotoxic chemotherapy
por: Maldonado, Edward B, et al.
Publicado: (2020)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
por: Haslam, Alyson, et al.
Publicado: (2019)

Characteristics of Facebook’s third-party medical fact checkers
por: Haslam, Alyson, et al.
Publicado: (2022)

Comparability of Control and Comparison Groups in Studies Assessing Long COVID
por: Haslam, Alyson, et al.
Publicado: (2023)

Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022
por: Mousavi, Idine, et al.
Publicado: (2022)

Additional considerations for assessing COVID-19 impact on dengue transmission – Authors' reply
por: Brady, Oliver J, et al.
Publicado: (2022)

Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay
por: Lyu, Nana, et al.
Publicado: (2020)

Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer
por: Wang, Fulong, et al.
Publicado: (2023)

Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment
por: Olivier, Timothée, et al.
Publicado: (2022)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

In Reply to ‘Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations’
por: Fernandes, Guillaume, et al.
Publicado: (2022)

Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
por: Chakrabarti, Sakti, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j7fa0fqppcu7tv1o6krvb8p0sa